The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein.
Open Access
- 15 October 1993
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 90 (20) , 9237-9241
- https://doi.org/10.1073/pnas.90.20.9237
Abstract
The Epstein-Barr virus nuclear antigen EBNA-2 is essential for Epstein-Barr virus-induced immortalization of B cells. EBNA-2 is a transcriptional activator capable of modifying the expression of specific viral and cellular genes. However, the mechanism of EBNA-2 transactivation has been an enigma. We used a fractionated extract of CA46 lymphoblastoid cells and bacterially expressed EBNA-2 polypeptides to demonstrate that EBNA-2 is targeted to the Epstein-Barr virus latency C promoter (Cp) through interaction with a cellular DNA binding protein designated Cp binding factor 1 (CBF1). A glutathione S-transferase-EBNA-2 fusion protein containing aa 252-425 of EBNA-2 interacted with CBF1 to yield a slowly migrating complex in an electrophoretic mobility shift assay. Mutation of EBNA-2 aa 323 and 324, which lie within a highly conserved amino acid motif, abolished the interaction with CBF1. This same mutation also abolished the ability of EBNA-2 to activate the Cp in a cotransfection assay. The binding site for CBF1 was localized to residues -359 to -388 of the Cp by using an electrophoretic mobility shift assay and DNase I footprinting. Introduction of multiple copies of the CBF1 binding site upstream of a minimal heterologous promoter conferred EBNA-2 responsiveness on that promoter. Mutation of a core sequence CNGTGGGAA abolished CBF1 binding, and the mutated sequence was unable to mediate EBNA-2 transactivation. The CBF1 core sequence also occurs in other EBNA-2-responsive promoters suggesting that CBF1 may mediate EBNA-2 transactivation of both cellular and viral targets.Keywords
This publication has 19 references indexed in Scilit:
- The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter.The EMBO Journal, 1993
- A region of herpes simplex virus VP16 can substitute for a transforming domain of Epstein-Barr virus nuclear protein 2.Proceedings of the National Academy of Sciences, 1992
- The herpes simplex virus trans-activator VP16 recognizes the Oct-1 homeo domain: evidence for a homeo domain recognition subdomain.Genes & Development, 1991
- A Survey of Epstein-Barr Virus DNA in Lymphoid Tissue: Frequent Detection in Hodgkin’s DiseaseAmerican Journal of Clinical Pathology, 1989
- Lymphocytes activated by the epstein-barr virus to produce immunoglobulin do not express CD23 or become immortalizedInternational Journal of Cancer, 1988
- Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells.Proceedings of the National Academy of Sciences, 1987
- Purified transcription factor AP-1 interacts with TPA-inducible enhancer elementsCell, 1987
- Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.Proceedings of the National Academy of Sciences, 1987
- Early events in Epstein-Barr virus infection provide a model for B cell activation.The Journal of Experimental Medicine, 1985
- U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2.Proceedings of the National Academy of Sciences, 1984